Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing
- 20 June 2024
- journal article
- review article
- Published by Tsinghua University Press in Nano Research
- Vol. 17 (10) , 8904-8925
Abstract
The continued development of clustered regularly interspaced short palindromic repeats (CRISPR) technology has the potential to greatly impact clinical medicine, particularly for disease diagnosis and treatment. Despite high demand for the in vivo delivery of CRISPR-based therapies, significant challenges persist. These include rapid degradation by enzymes, inefficient disease site targeting, and the risk of undesired off-target outcomes. Nanoparticulate platforms, with their tailorable properties, have been engineered to efficiently package CRISPR payloads in various formats, including as plasmid DNA, mRNA, and ribonucleoprotein complexes, for in vivo delivery. Among them, recombinant adeno-associated viruses, virus-like particles, and lipid nanoparticles have displayed exceptional promise. This review will discuss the development of these and other nanocarriers for in vivo CRISPR-based genome editing.Keywords
This publication has 297 references indexed in Scilit:
- Immunostimulatory DNA Hydrogel Enhances Protective Efficacy of Nanotoxoids against Bacterial InfectionAdvanced Materials, 2023
- Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome EditingChemBioChem, 2021
- Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticlesBioengineering & Translational Medicine, 2021
- Spatiotemporal Control of CRISPR/Cas9 Function in Cells and Zebrafish using Light‐Activated Guide RNAAngewandte Chemie International Edition, 2020
- Remote‐Loaded Platelet Vesicles for Disease‐Targeted Delivery of TherapeuticsAdvanced Functional Materials, 2018
- Cell Membrane Coating NanotechnologyAdvanced Materials, 2018
- Immunity to CRISPR Cas9 and Cas12a therapeuticsWIREs Mechanisms of Disease, 2017
- Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNAAngewandte Chemie International Edition, 2016
- Genome Editing of Monogenic Neuromuscular DiseasesJAMA Neurology, 2016
- Conjugation and Evaluation of Triazole‐Linked Single Guide RNA for CRISPR‐Cas9 Gene EditingChemBioChem, 2016